参考文献/References:
[l]Jemal A.Siegel R,Ward E,et al.Cancer statistics.2008.CA Cancer J Clin,2008,58(2):71-96.
[2] 宋平平.贾慧.张百江.FDC-PET及PET-CT在肺癌中的应用价值.肿瘤防治杂志.2004.1l(1):103-106.
[3] 张晓颖.韩冰。侯跃芳.等.非小细胞肺癌淋巴结分期的PET/CT准确性评价——Meta分析.中国临床医学影像杂志.2009.20(3):184-188.
[4] 于丽娟,锻玉,梁秀艳.等.F-FDG PET/CT显像在肺癌诊断及探查转移灶中的价值.中国医学影像技术.2007.23(4):605-607.
[5] Martini N,Kris MG.Flehinger BJ,et al.Preopemtive chemotherapy for stage Ills (N2) lung cancer.the Slosh-Kettering experience with 136 patients.Ann Thorar Surg.1993.55(6):1365-1373.
[6] Ryu JS,Choi NC,Fischman AJ,et al.FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradio-stherapy:correlation with histopathology.Lung Cancer,2002,35(2):179-187.
[7] Santo A,Genestreti G,Sara T,et al.Neo-adjuvant chemotherapy in non-small cell lung eancer(NSCLC).Ann Oneol,2006,17(Suppl 5):v55-v61.
[8] Mac Manus MP,Hicks RJ,Matthews JP,et al Positron emission tomography is superior to computed tomography scanning for responseassessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer.J Clin Oncol,2003,21(7):1285-1292.
[9] Hoekstra CJ,Stroobants SG,Smit EF,et al.Prognostic relevance of response evaluation using[18F]-2-fluoro-2-deoxy-D-giucose positron emission tomography in patients with locally advanced non-small-cell lung cancer.J Clin Oncol,2005,23(33):8362-8370.
[10] Vansteenkiste JF.Stroobants SG,De Leyn PR et al Potential use of FDG-PET scan after induction chemotherapy in surgically staged Ⅲ a-N2 non-small-cell lung cancer:a prospective pilot study.The Leuven Lung Cancer Group.Ann Oncol.1998.9(11):1193-1198.
[11] Cerfolio RJ,Bryant AS,Winokur TS,et al.Repeat FDG-PET after neoadjuvant therapy is a predictor of pathologic response in patients with non-small celllung cancer.Ann Thorac Surg,2004,78(6):1903-1909
[12] Rivera MP.Multimodality therapy in the treatment of lung cancer. Semin Respir Crit Care Med.2004.25(Suppl l):3-10.
[13] Weber WA Petersen V.Schmidt B,et al.Positron emission tomography in non small-cell lung cacer.prediction of response to chemotherapy by quantitative assessment of glucose use.J Clin OneoL 2003.21(14):265l-2657.
[14] Pöttgen C.Lecegrün S,Theegarten D,et al.Value of 18F-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in non-small-cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemomdiotherapy.Clin Cancer Res,2006,12(1):97-106.
[15] Coffin J,Baral S,Tu D.et al.Objective responses in patients with malignant melanoma or renal cell cancer in early clinical studies do not predict regulatory approval.Clin Cancer Res,2005,ll(16):5928-5934.
[16] van den Boogaart V.de Langen A,Groen HJ,et al.A phase Ⅱ study of erlotinib (E) and bevaeizumab (B) in chemo naive patients (pts) with locally advanced or metastatic non small cell lung cancer (NSCLC):Predictive value of molecular imaging.J Clin Oncol,2008, 26(15s):8055.
[17] Yamamoto Y,Kameyama R,Murota M,et al.Early assessment of thera-peutic response using FDG PET in small cell lung cancer.Mol Imaging Biol,2009.1l(6):467-472.
[18] Fischer BM.Mortensen J,Langer SW.et al.PET/CT imaging in response evaluation of patients with small cell lung cancer.Lung Cancer,2006.54(1l:41-49.
[19] Spaepen K.Stroobants S.Dupont P,et al.[18F]FDG PET monitoring of tumour response to chemotherapy:does[18F]FDG uptake correlate with the viable tumour cell fraction.Eur J Nuel Med Mol Imaging, 2003.30(5):682-688.
[20] Boellaard R,Oyen WJ,Hoekstra CJ,et al.The Netherlands protocol for standardisation of FDG whole body PET studies in multi-center trials.Eur J Nucl Med Mol Imaging,2008.35{12):2320-2333.
[21] Minn H.Zasadny KR.Quint LE,et al.Lung cancer reproducibility of quantitative measurements for evaluating 2-[F-18]-fluoro-2-deoxy D-glucose uptake at PET.Radiology.1995.196(1):167-173.
[22] Weber WA.Ziegler SI。Thödtmann R,et al.Reproducibility of metabolic measurements in malignant tumors using FDG PET.J Nucl Med,1999.40(11):1771-1777.
[23] Port JL Kent MS.Korst RJ.et al.Positron emission tomography scanning poorly predicts response to preoperative chemotherapy in non-small cell lung cancer.Ann Thorac Surg.2004.77(1):254-259.
相似文献/References:
[1]何燕,苏晋,郑晓霞,等.P-糖蛋白抑制剂在PET显像中的应用研究[J].国际放射医学核医学杂志,2016,40(1):1.[doi:10.3760/cma.j.issn.1673-4114.2016.01.001]
He Yan,Su Jin,ZhengXiaoxia,et al.Developing P-glycoprotein inhibitor marked by PET[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):1.[doi:10.3760/cma.j.issn.1673-4114.2016.01.001]
[2]周玉祥,蓝博文,黄春榆,等.64排螺旋CT冠状动脉血管成像诊断冠状动脉-肺动脉瘘的应用价值[J].国际放射医学核医学杂志,2016,40(1):26.[doi:10.3760/cma.j.issn.1673-4114.2016.01.006]
Zhou Yuxiang,Lan Bowen,Huang Chunyu,et al.Clinical value of coronary artery-pulmonary artery fistula revealed by 64-slice spiral CT coronary angiography[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):26.[doi:10.3760/cma.j.issn.1673-4114.2016.01.006]
[3]陈超坤,刘亮,傅飞先,等.囊性胸腺瘤和囊性畸胎瘤的影像学特征及鉴别诊断[J].国际放射医学核医学杂志,2016,40(1):31.[doi:10.3760/cma.j.issn.1673-4114.2016.01.007]
Chen Chaokun,Liu Liang,Fu Feixian,et al.Imaging features and differential diagnosis of cystic thymoma and cystic teratoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):31.[doi:10.3760/cma.j.issn.1673-4114.2016.01.007]
[4]许飞,刘建军,黄钢,等.PET乏氧显像在预测肿瘤乏氧及指导临床治疗中的应用进展[J].国际放射医学核医学杂志,2016,40(1):35.[doi:10.3760/cma.j.issn.1673-4114.2016.01.008]
Xu Fei,Liu Jianjun,Huang Gang,et al.The application of hypoxia imaging with PET in predicting tumor hypoxia and guiding clinical therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):35.[doi:10.3760/cma.j.issn.1673-4114.2016.01.008]
[5]胡伟,赵军.小胶质细胞在AD炎性机制中的作用及其常见PET显像剂的应用进展[J].国际放射医学核医学杂志,2016,40(1):44.[doi:10.3760/cma.j.issn.1673-4114.2016.01.009]
Hu Wei,Zhao Jun.Microglia’s Alzheimer disease inflammatory mechanisms and progress of its common application in PET imaging agents[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):44.[doi:10.3760/cma.j.issn.1673-4114.2016.01.009]
[6]岳进,苏丽萍.全身MRI与PET/CT在淋巴瘤骨髓浸润诊断及预后中的作用[J].国际放射医学核医学杂志,2016,40(1):50.[doi:10.3760/cma.j.issn.1673-4114.2016.01.010]
Yue Jin,Su Lipin.Function of whole-body MRI and PET/CT in the diagnosis and prognosis of lymphoma with bone marrow infiltration[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):50.[doi:10.3760/cma.j.issn.1673-4114.2016.01.010]
[7]麦卫平,张永林.能谱CT成像在肺癌诊断中的应用研究进展[J].国际放射医学核医学杂志,2016,40(1):77.[doi:10.3760/cma.j.issn.1673-4114.2016.01.015]
Mai Weiping,Zhang Yonglin.Research progress of spectral imaging in the diagnosis of lung cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):77.[doi:10.3760/cma.j.issn.1673-4114.2016.01.015]
[8]李海峰,张晓军,李云钢,等.国产模块LOOP环改良法合成11C-蛋氨酸[J].国际放射医学核医学杂志,2016,40(2):106.[doi:10.3760/cma.j.issn.1673-4114.2016.02.004]
Li Haifeng,Zhang Xiaojun,Li Yungang,et al.Synthesis of 11C-methionine on home-made module by the improved LOOP method[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):106.[doi:10.3760/cma.j.issn.1673-4114.2016.02.004]
[9]周翠屏,廖俊杰,何国华,等.原发性肠系膜巨大淋巴结增生症的MSCT表现与病理对照分析[J].国际放射医学核医学杂志,2016,40(3):175.[doi:10.3760/cma.j.issn.1673-4114.2016.03.003]
Zhou Cuiping,Liao Junjie,He Guohua,et al.Primary mesenteric Castleman disease:MSCT findings with histopathologic correlation[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):175.[doi:10.3760/cma.j.issn.1673-4114.2016.03.003]
[10]李海峰,张晓军,张锦明.多巴胺转运蛋白显像剂11C-β-CFT在帕金森病中的应用研究[J].国际放射医学核医学杂志,2016,40(3):218.[doi:10.3760/cma.j.issn.1673-4114.2016.03.011]
Li Haifeng,Zhang Xiaojun,Zhang Jinming.Review of the use of dopamine transporter imaging agent 11C-β-CFT for diagnosing Parkinson disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):218.[doi:10.3760/cma.j.issn.1673-4114.2016.03.011]
[11]张莹莹,王振光,孔艳.PET/CT显像在肺间质纤维化中的应用进展[J].国际放射医学核医学杂志,2016,40(1):55.[doi:10.3760/cma.j.issn.1673-4114.2016.01.011]
Zhang Yingying,Wang Zhenguang,Kong Yan.Application advancement on PET/CT in pulmonary interstitial fibrosis[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):55.[doi:10.3760/cma.j.issn.1673-4114.2016.01.011]
[12]史文杰,孟召伟,谭建.基于Deauville标准探讨18F-FDG PET/CT在霍奇金淋巴瘤复发诊断中的应用价值[J].国际放射医学核医学杂志,2016,40(2):120.[doi:10.3760/cma.j.issn.1673-4114.2016.02.007]
Shi Wenjie,Meng Zhaowei,Tan Jian.Value of 18F-FDG PET/CT on diagnosis of Hodgkin lymphoma recurrence using Deauville criterion[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):120.[doi:10.3760/cma.j.issn.1673-4114.2016.02.007]
[13]尤阳,轩昂,张杰,等.淋巴瘤患者大脑静息葡萄糖代谢改变[J].国际放射医学核医学杂志,2016,40(4):255.[doi:10.3760/cma.j.issn.1673-4114.2016.04.003]
You Yang,Xuan Ang,Zhang Jie,et al.Changes in resting-state brain glucose metabolism in patients with lymphoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):255.[doi:10.3760/cma.j.issn.1673-4114.2016.04.003]
[14]王朋,崔邦平,代文莉,等.18F-FDG PET/CT在前列腺癌中的应用进展[J].国际放射医学核医学杂志,2016,40(4):277.[doi:10.3760/cma.j.issn.1673-4114.2016.04.008]
Wang Peng,Cui Bangping,Dai Wenli,et al.Progress in the application of 18F-FDG PET/CT in prostate cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):277.[doi:10.3760/cma.j.issn.1673-4114.2016.04.008]
[15]李菲,黄俊星,张俊.18F-FDG PET/CT在食管癌中的临床应用[J].国际放射医学核医学杂志,2016,40(4):282.[doi:10.3760/cma.j.issn.1673-4114.2016.04.009]
Li Fei,Huang Junxing,Zhang Jun.The clinical application of 18F-FDG PET/CT in esophageal cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):282.[doi:10.3760/cma.j.issn.1673-4114.2016.04.009]
[16]张巍,杨珂.18f正电子放射性药物生产及使用中医务人员的受照剂量研究[J].国际放射医学核医学杂志,2015,39(5):420.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 016]
zhang wei,yang ke..the research of radiation dose of 18f-fdg to pet/ct related personnel[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):420.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 016]
[17]曹登敏,林美福,陈文新,等.继发性骨淋巴瘤的18F-FDG PET/CT影像学表现[J].国际放射医学核医学杂志,2016,40(6):403.[doi:10.3760/cma.j.issn.1673-4114.2016.06.001]
Cao Dengmin,Lin Meifu,Chen Wenxin,et al.Analysis on 18F-FDG PET/CT imaging characteristics in secondary bone lymphoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):403.[doi:10.3760/cma.j.issn.1673-4114.2016.06.001]
[18]李生栩,唐明灯,林端瑜,等.18F-FDG PET/CT在胸段食管鳞癌淋巴结转移中的诊断价值[J].国际放射医学核医学杂志,2016,40(6):408.[doi:10.3760/cma.j.issn.1673-4114.2016.06.002]
Li Shengxu,Tang Mingdeng,Lin Duanyu,et al.Value of 18F-FDG PET/CT in detecting metastatic lymph nodes of thoracic esophageal squamous cell carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):408.[doi:10.3760/cma.j.issn.1673-4114.2016.06.002]
[19]张莹莹,王振光,武凤玉,等.特发性肺间质纤维化HRCT病变区与非病变区18F-FDG PET/CT表现分析[J].国际放射医学核医学杂志,2016,40(6):414.[doi:10.3760/cma.j.issn.1673-4114.2016.06.003]
Zhang Yingying,Wang Zhenguang,Wu Fengyu,et al.18F-FDG PET/CT imaging analysis of regions with abnormal and normal pulmonary parenchyma on high resolution CT in idiopathic pulmonary fibrosis patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):414.[doi:10.3760/cma.j.issn.1673-4114.2016.06.003]
[20]张毓艺,姚稚明.18F-FDG PET/CT对非小细胞肺癌淋巴结分期诊断价值的研究进展[J].国际放射医学核医学杂志,2016,40(6):447.[doi:10.3760/cma.j.issn.1673-4114.2016.06.009]
Zhang Yuyi,Yao Zhiming.The progress of 18F-FDG PET/CT in the diagnosis of N-staging of non-small cell lung cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):447.[doi:10.3760/cma.j.issn.1673-4114.2016.06.009]